Clara Steiner

Looking forward to attending my 1st @ASCO #GU25 and so grateful to receive a @ConquerCancerFd Merit Award for our work! Would not have been possible without my mentors @VincentWenxinXu + @DrChoueiri and the team!!

And that is wrap for #KCRS2025 @HHammersMD @advocatekidneys @kidneycan

Check out these hand-drawn posters from #KCRS2025, detailing everything from federal funding to clinical updates. #kcsm | @kidneycan

A sharp and insightful talk at #KCRS25 about KIM-1 in JAVELIN Renal 101 by my dear colleague @MarcMachaalani — another key step in the evolving story of KIM-1 in RCC with more to come!! @VincentWenxinXu @DrChoueiri

Updated KEYNOTE-B61 data with a 50% ORR and durable responses in patient with variant histology RCC A lot of hope for 1st line therapy in that setting and a wonderful talk by @AlbigesL #KCRS25 @OncoAlert

Takeaways from @VincentWenxinXu 's majestic talk on biomarkers: - Several biomarkers have been studied in RCC - Current biomarkers in RCC do not correspond to patient's goals - The future is in integrative biomarkers - Let's get back to work to answer all the different questions…

Thank you @CJSTRAV3 @kidneycan

#KCRS25 Session 1 highlighted how federally funded research, especially through programs like the KCRP, drives real-world progress in kidney cancer treatment and patient outcomes. Building a Trial Consortium with @EJonasch Personalized Vaccines in Kidney Cancer with @BraunMDPhD…

Clinical and scientific updates in RCC Kicking off day 2 of #KCRS25 with all you need to know if you've been living on the moon for the last year Inspirational first talk by Dr. McDermott setting the tone for the years to come @OncoAlert

What an incredible slide from @VincentWenxinXu at #KCRS2025 depicting some of the individuals that have contributed to biomarker research in RCC 🔬. “Biomarkers are a lot of work, but they will reduce both overtreatment and undertreatment” @kidneycan @OncoAlert

Thank you so much for highlighting our work Yüksel!

.@DrChoueiri takes the stage to present data from the phase 1 ARC-20 trial that shows that the combination of HIF2 inhibitor casdatifan plus cabo has promising clinical activity (cORR 46%) and an acceptable safety profile in pretreated pts w/ mRCC. #ASCO25 @ASCO @OncoAlert

📢 #ASCO25 | Major advance in mCRPC with bone mets by the one and only @DrRanaMcKay | Olaparib + Ra-223 vs Ra-223 Alone Ph. II | In a randomized study n=120, this combo doubled rPFS (8.6 vs 4.0 mo; HR 0.51) in both HRR-mut and HRR-wt patients — with manageable safety. A…

Fascinating data straight from 🇧🇷 with amazing oncologist and colleague @pablombarrios about different treatment patterns in private vs public settings #ASCO25 @OncoAlert

🌟🔬 Exploratory HRRm analyses from #TALAPRO2 – #ASCO25 Presented by Dr. Stefanie Zschaebitz🌟 @OncoAlert @APCCC_Lugano @Silke_Gillessen @AOmlin TALA + ENZA improved outcomes vs ENZA + PBO in mCRPC with HRRm, especially in BRCA/ATM/CDK12: 🧬 BRCA2: ▪️ ORR: 86.4% vs 31.0% ▪️…

👉🏻 Our very own @chadihcmd presenting @ASCO a real-world study showing most patients do not undergo NGS testing, and a substantial proportion receive it only near end of life—limiting its clinical utility and impact on treatment decisions. #ASCO25 @Huntsman_GU @neerajaiims

📢 #ASCO25 | ANZUP 1301 Ph III | HR NMIBC (~500 pts): Mitomycin + BCG vs BCG alone—combination arm met primary endpoint with significant DFS benefit (HR 0.70; 2‑yr DFS 78% vs 65%); recurrence reduced. Dickon Hayne et al. Full abstract → asco.org/abstracts-pres……

📢 #ASCO25 | NIAGARA ctDNA Analysis | MIBC pts on perioperative durvalumab: Baseline ctDNA+ in a subset linked to shorter EFS; early ctDNA clearance after D associated with improved DFS; persistent ctDNA post-surgery predicted relapse. Thomas Powles et al. Full abstract →…

📢 #ASCO25 | EV‑302 Ph III | la/mUC Responders: Among pts achieving cCR, EV + P arm showed 74% 2‑yr maintained cCR vs 32% with chemo; median OS in responders was 33.8 mo vs 16.1 mo (HR 0.51; P<0.001). Shilpa Gupta et al. Full abstract → meetings.asco.org/abstracts-pres……

📢 #ASCO25 | JAVELIN Bladder Medley Ph II | aUC 1L maintenance: Avelumab + SG vs Avelumab alone—median PFS 11.17 mo vs 3.75 mo (HR 0.49; 95% CI 0.31–0.76); any‑grade TRAEs 97.3% vs 63.9%, G≥3 54.8% vs 17.9%. Jeannie Hoffman‑Censits et al. Full abstract…

📢 #ASCO25 | CheckMate 901 | Cis‑ineligible mUC: NIVO 1 mg/kg + IPI 3 mg/kg Q3W×4→NIVO 480 mg Q4W vs gem‑carbo Q3W×6: Any‑grade TRAEs 89% (G3–4 47%) vs 93% (G3–4 76%); TRAE‑related discontinuation 31% vs 14%; 8 toxicity‑related deaths (7 vs 1); no OS benefit in…